| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7390791 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(1 year, 6 months from now) | |
| US9296769 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| US8754065 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7803788 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucoleotide analogues |
Feb, 2022
(1 year, 7 months ago) | |
|
US7390791 (Pediatric) | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Oct, 2025
(2 years from now) | |
|
US9296769 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(9 years from now) | |
|
US8754065 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(9 years from now) | |
Vemlidy is owned by Gilead Sciences Inc.
Vemlidy contains Tenofovir Alafenamide Fumarate.
Vemlidy has a total of 7 drug patents out of which 1 drug patent has expired.
Expired drug patents of Vemlidy are:
- US7803788
Vemlidy was authorised for market use on 10 November, 2016.
Vemlidy is available in tablet;oral dosage forms.
Vemlidy can be used as treatment of chronic hepatitis b in adult patients.
The generics of Vemlidy are possible to be released after 15 February, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M (M) | Aug 22, 2023 |
| New Patient Population (NPP) | Oct 17, 2025 |
Drugs and Companies using TENOFOVIR ALAFENAMIDE FUMARATE ingredient
Market Authorisation Date: 10 November, 2016
Treatment: Treatment of chronic hepatitis b in adult patients
Dosage: TABLET;ORAL
VEMLIDY family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic